Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995694039> ?p ?o ?g. }
- W1995694039 endingPage "1593" @default.
- W1995694039 startingPage "1593" @default.
- W1995694039 abstract "Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review Xuepeng He, Kai Yang, Peng Chen, Bing Liu, Yuan Zhang, Fang Wang, Zhi Guo, Xiaodong Liu, Jinxing Lou, Huiren Chen Department of Hematology, General Hospital of Beijing Military Area of PLA, Beijing, People’s Republic of China Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate significant benefit for MM patients with improved survival, all MM patients still relapse. Arsenic trioxide (ATO) is the most active single agent in acute promyelocytic leukemia, the antitumor activity of which is partly dependent on the production of reactive oxygen species. Due to its multifaceted effects observed on MM cell lines and primary myeloma cells, Phase I/II trials have been conducted in heavily pretreated patients with relapsed or refractory MM. Therapy regimens varied dramatically as to the dosage of ATO and monotherapy versus combination therapy with other agents available for the treatment of MM. Although ATO-based combination treatment was well tolerated by most patients, most trials found that ATO has limited effects on MM patients. However, since small numbers of patients were randomized to different treatment arms, trials have not been statistically powered to determine the differences in progression-free survival and overall survival among the experimental arms. Therefore, large Phase III studies of ATO-based randomized controlled trials will be needed to establish whether ATO has any potential beneficial effects in the clinical setting. Keywords: multiple myeloma, arsenic trioxide, clinical trial, therapy, meta-analysis" @default.
- W1995694039 created "2016-06-24" @default.
- W1995694039 creator A5002661071 @default.
- W1995694039 creator A5014528965 @default.
- W1995694039 creator A5014869364 @default.
- W1995694039 creator A5031013005 @default.
- W1995694039 creator A5031767581 @default.
- W1995694039 creator A5035168940 @default.
- W1995694039 creator A5059996528 @default.
- W1995694039 creator A5074039714 @default.
- W1995694039 creator A5076415782 @default.
- W1995694039 creator A5091094911 @default.
- W1995694039 date "2014-09-01" @default.
- W1995694039 modified "2023-09-28" @default.
- W1995694039 title "Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review" @default.
- W1995694039 cites W1504632256 @default.
- W1995694039 cites W1559603064 @default.
- W1995694039 cites W1692919389 @default.
- W1995694039 cites W1748388485 @default.
- W1995694039 cites W1755981784 @default.
- W1995694039 cites W1759028523 @default.
- W1995694039 cites W1777794242 @default.
- W1995694039 cites W192794212 @default.
- W1995694039 cites W1965553476 @default.
- W1995694039 cites W1971017479 @default.
- W1995694039 cites W1978377409 @default.
- W1995694039 cites W1997230847 @default.
- W1995694039 cites W2007998678 @default.
- W1995694039 cites W2008204305 @default.
- W1995694039 cites W2014922333 @default.
- W1995694039 cites W2016089374 @default.
- W1995694039 cites W2019350797 @default.
- W1995694039 cites W2042604243 @default.
- W1995694039 cites W2046818057 @default.
- W1995694039 cites W2070009086 @default.
- W1995694039 cites W2070227063 @default.
- W1995694039 cites W2079208747 @default.
- W1995694039 cites W2086564382 @default.
- W1995694039 cites W2087204302 @default.
- W1995694039 cites W2092000830 @default.
- W1995694039 cites W2094103097 @default.
- W1995694039 cites W2106969589 @default.
- W1995694039 cites W2118310862 @default.
- W1995694039 cites W2122465033 @default.
- W1995694039 cites W2129662445 @default.
- W1995694039 cites W2131790570 @default.
- W1995694039 cites W2138838585 @default.
- W1995694039 cites W2142423276 @default.
- W1995694039 cites W2143621111 @default.
- W1995694039 cites W2148059446 @default.
- W1995694039 cites W2154374454 @default.
- W1995694039 cites W2155508035 @default.
- W1995694039 cites W2165948908 @default.
- W1995694039 cites W2245046744 @default.
- W1995694039 cites W2245958628 @default.
- W1995694039 cites W2262257182 @default.
- W1995694039 cites W2274495895 @default.
- W1995694039 cites W2327751163 @default.
- W1995694039 cites W2414621513 @default.
- W1995694039 cites W2421641055 @default.
- W1995694039 cites W2588243155 @default.
- W1995694039 cites W2036037977 @default.
- W1995694039 doi "https://doi.org/10.2147/ott.s67165" @default.
- W1995694039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4166211" @default.
- W1995694039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25246802" @default.
- W1995694039 hasPublicationYear "2014" @default.
- W1995694039 type Work @default.
- W1995694039 sameAs 1995694039 @default.
- W1995694039 citedByCount "11" @default.
- W1995694039 countsByYear W19956940392012 @default.
- W1995694039 countsByYear W19956940392015 @default.
- W1995694039 countsByYear W19956940392016 @default.
- W1995694039 countsByYear W19956940392017 @default.
- W1995694039 countsByYear W19956940392022 @default.
- W1995694039 countsByYear W19956940392023 @default.
- W1995694039 crossrefType "journal-article" @default.
- W1995694039 hasAuthorship W1995694039A5002661071 @default.
- W1995694039 hasAuthorship W1995694039A5014528965 @default.
- W1995694039 hasAuthorship W1995694039A5014869364 @default.
- W1995694039 hasAuthorship W1995694039A5031013005 @default.
- W1995694039 hasAuthorship W1995694039A5031767581 @default.
- W1995694039 hasAuthorship W1995694039A5035168940 @default.
- W1995694039 hasAuthorship W1995694039A5059996528 @default.
- W1995694039 hasAuthorship W1995694039A5074039714 @default.
- W1995694039 hasAuthorship W1995694039A5076415782 @default.
- W1995694039 hasAuthorship W1995694039A5091094911 @default.
- W1995694039 hasBestOaLocation W19956940391 @default.
- W1995694039 hasConcept C104317684 @default.
- W1995694039 hasConcept C126322002 @default.
- W1995694039 hasConcept C143998085 @default.
- W1995694039 hasConcept C168563851 @default.
- W1995694039 hasConcept C185592680 @default.
- W1995694039 hasConcept C190283241 @default.
- W1995694039 hasConcept C2776063141 @default.
- W1995694039 hasConcept C2776364478 @default.
- W1995694039 hasConcept C2776601000 @default.
- W1995694039 hasConcept C2776999253 @default.
- W1995694039 hasConcept C2777478702 @default.